93 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
SGEN Seattle Genetics, Inc. $76.15 $12.09B N/A
Article Searches
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors http://www.zacks.com/stock/news/431013/roches-rozlytrek-gets-approval-in-japan-for-solid-tumors?cid=CS-ZC-FT-431013 Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark http://www.zacks.com/stock/news/404524/seattle-genetics-sgen-q1-loss-narrows-revenues-top-mark?cid=CS-ZC-FT-404524 Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
SEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/26/seattle-genetics-inc-sgen-q1-2019-earnings-confere.aspx?source=iedfolrf0000001 Apr 26, 2019 - SGEN earnings call for the period ending March 31, 2019.
Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4256999-seattle-genetics-inc-sgen-ceo-clay-siegall-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 26, 2019 - Seattle Genetics, Inc. (NASDAQ:SGEN) Q1 2019 Earnings Conference Call April 25, 2019 17:00 ET Company Participants Peggy Pinkston - VP, IR Clay Siegall - President & CEO Roger Dansey - Chief Medic
INTC, F, MAT and SGEN among notable after hour movers https://seekingalpha.com/news/3454660-intc-f-mat-sgen-among-notable-hour-movers?source=feed_news_all Apr 25, 2019 - Top Gainers: EHTH +12.2%. MAT +11.9%. F +7.9%. PRO +7.6%. GRUB +5.1%.Top Losers: ATEN -15.8%. INTC -7.6%. BEAT -6.9%. PFPT -6.3%. SGEN -5.2%.
After-Hours Report: EHTH +13%, MAT +10.3%, F +9%, TEN -14.8%, PFPT -7.9%, SGEN -7.9% on earnings/guidance http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=NS20190425172356AfterHoursReport Apr 25, 2019 - The S&P 500 (-0.04%) finished fractionally lower on Thursday, although strong earnings reports from
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know http://www.zacks.com/stock/news/386999/will-seattle-genetics-sgen-report-negative-earnings-next-week-what-you-should-know?cid=CS-ZC-FT-386999 Apr 18, 2019 - Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Seattle Genetics, Astellas Report Positive Cancer Study Data http://www.zacks.com/stock/news/367467/seattle-genetics-astellas-report-positive-cancer-study-data?cid=CS-ZC-FT-367467 Mar 29, 2019 - Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

Pages: 123456...10

Page 1>